Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
- Conditions
- Recurrent Multiple Myeloma
- Interventions
- Procedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Bone ScanProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2025-01-21
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 37
- Registration Number
- NCT06785415
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Conditions
- MyelomaMultiple MyelomaRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 49
- Registration Number
- NCT06518551
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Registration Number
- NCT06232707
- Locations
- 🇺🇸
Local Institution - 0088, Los Angeles, California, United States
🇺🇸Local Institution - 0324, Baltimore, Maryland, United States
🇦🇺Local Institution - 0022, Waratah, New South Wales, Australia
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- 🇬🇷
251 Airforces Hospital, Athens, Greece
🇹🇷Ankara University Medical Faculty, Ankara, Turkey
🇹🇷Liv Hospital Ankara, Ankara, Turkey
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT06163040
- Locations
- 🇨🇳
China Medical University Hospital, Taoyuan City, Taiwan
🇨🇳Chang Gung Memorial Hospital- Chiayi, Chiayi City, Chiayi, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- 🇺🇸
University of Alabama at Birmingham - Main /ID# 261434, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Hospital - Phoenix /ID# 263326, Phoenix, Arizona, United States
🇺🇸Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇫🇷
Hôpital NOVO, Pontoise, Val-d'oise, France
🇺🇸Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Abdullah Khan
- Target Recruit Count
- 27
- Registration Number
- NCT05981209
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT05730036
- Locations
- 🇮🇱
The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇧🇷Instituto DOr de Pesquisa e Ensino, Sao Paulo, Brazil
🇧🇷AC Camargo Cancer Center, Sao Paulo, Brazil
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 7
- Registration Number
- NCT05560399
- Locations
- 🇺🇸
Icahn School of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.